BioNTech präsentiert
BioNTech präsentiert auf der ASCO-Jahrestagung 2024 klinische Daten-Updates zu innovativen Immuntherapie-Kandidaten
May 21, 2024 06:45 ET | BioNTech SE
MAINZ, Deutschland, 21. Mai 2024 – BioNTech SE (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) wird auf der diesjährigen Jahrestagung der American Society of Clinical Oncology („ASCO“), die vom 31....
BioNTech to Present
BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO Annual Meeting 2024
May 21, 2024 06:45 ET | BioNTech SE
MAINZ, Germany, May 21, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected programs from the Company’s diversified immuno-oncology pipeline at...
Logo.png
Abstract on Phase 2 Study with IMUNON’s IMNN-001 Plus Bevacizumab Accepted for Presentation at the American Society of Clinical Oncology Annual Meeting
May 15, 2024 08:30 ET | Imunon, Inc.
LAWRENCEVILLE, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and...
Nouveau Logo communiqué de presse.JPG
Theratechnologies présentera des données à long terme sur l’efficacité, l’innocuité et la pharmacocinétique de l’utilisation du TH1902 (sudocétaxel zendusortide) dans les tumeurs solides lors du Congrès 2024 de l’ASCO
May 02, 2024 07:30 ET | Theratechnologies
Dévoilement de données à long terme des parties 1 et 2 de l’essai clinique de phase I portant sur le sudocétaxel zendusortide dans les tumeurs solidesLa partie 3 de la phase I de l’essai sur le cancer...
Nouveau Logo communiqué de presse.JPG
Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting
May 02, 2024 07:30 ET | Theratechnologies
First long-term data presentation from Parts 1 and 2 of the Phase 1 clinical trial of sudocetaxel zendusortide in solid tumors Part 3 of Phase 1 trial in advanced ovarian cancer is ongoing MONTREAL,...
PasitheaLogo.png
Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting
April 29, 2024 07:59 ET | Pasithea
Pasithea Therapeutics' PAS-004 abstract accepted for ASCO poster presentation: novel MEK inhibitor shows promise for NF1 and cancer therapy.
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meeting
April 24, 2024 16:02 ET | FibroGen, Inc.
SAN FRANCISCO, April 24, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that clinical data from the dose escalation portion of the Phase 1b/2 study of FG-3246 in combination...
NMDP Awards Amy Scholars and Barbara Buchbinder Nurse Research Program grant
NMDP to Present New Stem Cell Transplantation Data at the 2024 American Society of Clinical Oncology Annual Meeting
April 24, 2024 10:43 ET | NMDP
NMDP to present new data on hematopoietic cell transplantation treatment effects in patients with hematological malignancies at ASCO.
cgoncology_cover.jpg
CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024
April 24, 2024 10:00 ET | CG Oncology Inc.
CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024
immunocore-logo-2018
Immunocore announces upcoming presentation and posters at ASCO 2024
April 24, 2024 10:00 ET | Immunocore Holdings plc
Immunocore announces upcoming presentation and posters at ASCO 2024 Phase 1 expansion data in immune checkpoints pre-treated cutaneous melanoma for brenetafusp (IMC-F106C targeting PRAME) to be...